5-(benzyloxy)-3-(tert-butyloxycarbonyl)-1-(hydroxymethyl)-1,2-dihydro-3H-benzindole | 122745-39-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-(benzyloxy)-3-(tert-butyloxycarbonyl)-1-(hydroxymethyl)-1,2-dihydro-3H-benzindole
• 英文别名: (+/-)-5-benzyloxy-3-(tert-butyloxycarbonyl)-1-(hydroxymethyl)-2,3-dihydro-1H-benz[e]indole；tert-butyl 5-(benzyloxy)-1-(hydroxymethyl)-1,2-dihydro-3H-benzo[e]indole-3-carboxylate；5-(Benzyloxy)-3-(tert-butyloxycarbonyl)-(hydroxymethyl)-1,2-dihydro-3H-benz[e) indole；tert-butyl 1-(hydroxymethyl)-5-phenylmethoxy-1,2-dihydrobenzo[e]indole-3-carboxylate
• CAS: 122745-39-5
• 化学式: C₂₅H₂₇NO₄
• 分子量: 405.494
• InChiKey: WGMIDKXPARNAEF-UHFFFAOYSA-N

物化性质

• 沸点：
  571.1±50.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(benzyloxy)-3-(tert-butyloxycarbonyl)-1-(hydroxymethyl)-1,2-dihydro-3H-benzindole 在 4-二甲氨基吡啶 、 lithium hydroxide 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 (-)-(1R)-5-(benzyloxy)-3-(tert-butyloxycarbonyl)-1-(hydroxymethyl)-1,2-dihydro-3H-benzindole
  参考文献：
  名称：

  CBI前体的拆分和并入（+）-cbi，（+）-CBI-CDPI 1，（+）-CBI-CDPI 2的合成：（+）-CC-1065的增强功能类似物。对亲电试剂反应性，DNA结合特性和细胞毒性潜力之间拟议关系的严格评估。

  摘要：

  直接CBI前体（+）-和（-）- 8的拆分及其随后并入（+）-和（-）-CBI-CDPI n的旋光增强功能类似物的详细信息描述了-CC-1065。与先前详细描述的亲电试剂反应性和细胞毒性潜能之间的直接关系形成鲜明对比的是，特性之间的逆向关系得到了详细描述。

  DOI：

  10.1016/s0040-4039(00)94629-x
• 作为产物：
  描述：

  5-(Benzyloxy)-3-(tert-butyloxycarbonyl)-1-<(tetrahydropyranyloxy)methyl>-1,2-dihydro-3H-benzindole 在 Amberlyst 15 作用下， 以 甲醇 为溶剂， 反应 6.0h， 以95%的产率得到5-(benzyloxy)-3-(tert-butyloxycarbonyl)-1-(hydroxymethyl)-1,2-dihydro-3H-benzindole
  参考文献：
  名称：

  An improved synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI): a simplified analog of the CC-1065 alkylation subunit

  摘要：

  A concise and improved synthesis of 11, the immediate precursor to N-BOC-CBI and related analogues of CC-1065 incorporating the 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one alkylation subunit, is detailed based on a direct 5-exo-trig aryl radical-alkene cyclization for 3-hydroxymethylindoline generation.

  DOI：

  10.1021/jo00036a023

文献信息

• Resolution of a CBI precursor and incorporation into the synthesis of (+)-cbi, (+)-CBI-CDPI1, (+)-CBI-CDPI2: enhanced functional analogs of (+)-CC-1065. A critical appraisal of a proposed relationship between electrophile reactivity, DNA binding properties, and cytotoxic potency.
  作者：Dale L Boger、Takayoshi Ishizaki

  DOI：10.1016/s0040-4039(00)94629-x

  日期：1990.1

  and its subsequent incorporation into (+)− and (−)-CBI-CDPIn, optically-active enhanced functional analogs of (+)-CC-1065, are described. In marked contrast to a previously detailed direct relationship between electrophile reactivity and cytotoxic potency, an inverse relationship between the properties is detailed.

  直接CBI前体（+）-和（-）- 8的拆分及其随后并入（+）-和（-）-CBI-CDPI n的旋光增强功能类似物的详细信息描述了-CC-1065。与先前详细描述的亲电试剂反应性和细胞毒性潜能之间的直接关系形成鲜明对比的是，特性之间的逆向关系得到了详细描述。
• [EN] ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS<br/>[FR] DIMÈRES D'ISOQUINOLIDINOBENZODIAZÉPINE (IQB)-1(CHLOROMÉTHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI)
  申请人：CELLERANT THERAPEUTICS INC

  公开号：WO2018071455A1

  公开（公告）日：2018-04-19

  Provided herein are isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers, antibody-drug conjugates comprising them and methods of use for killing cells and treating disease.

  本文提供了异喹啉苯二氮卓啶（IQB）-1（氯甲基）-2,3-二氢-1H-苯并[e]吲哚（CBI）二聚体，包括它们的抗体药物结合物，以及用于杀灭细胞和治疗疾病的方法。
• Effective Asymmetric Synthesis of 1,2,9,9a-Tetrahydrocyclopropa[<i>c</i>]benzo[<i>e</i>]indol-4-one (CBI)
  作者：David B. Kastrinsky、Dale L. Boger

  DOI：10.1021/jo035465x

  日期：2004.4.1

  A short, asymmetric synthesis of the 1,2,9,9a-tetrahydrocyclopropa[c]benzo[e]indol-4-one (CBI) analogue of the CC-1065 and duocarmycin alkylation subunits is detailed that employs an effective enzymatic desymmetrization reaction of prochiral diol 12 using a commercially available Pseudomonas sp. lipase. The optically active monoacetate (S)-13 is furnished in exceptional conversions (88%) and optical

  详细介绍了CC-1065和Duocarmycin烷基化亚基的1,2,9,9a-四氢环丙烷[ c ]苯并[ e ]吲哚-4-酮（CBI）类似物的短时不对称合成，该合成方法采用了有效的酶促脱对称反应。使用市售的Pseudomonas sp。制备前手性二醇12。脂肪酶。旋光性单乙酸酯（S）-13具有出色的转化率（88％）和旋光纯度（99％ee），可作为制备CBI任一对映异构体的中间体。同样，假单胞菌sp。脂肪酶解决了外消旋中间体19，以良好的转化率和光学纯度（99％ee）提供先进的CBI中间体，并提供了制备光学活性CBI衍生物的替代方法。
• Cyclopropylindole prodrugs
  申请人：ProCoron, Inc.

  公开号：US05646298A1

  公开（公告）日：1997-07-08

  The present invention describes cyclopropylindole cytotoxic prodrugs of formulas (I), (II) and (III) as shown in the specification. The present invention is also directed to a method for the site-specific treatment of neoplastic diseases in a mammal which method includes the following steps: (i) administering to an afflicted mammal an effective amount of a targeting agent- enzyme donor peptide conjugate wherein the targeting agent is selected from the group of antibodies, monoclonal antibodies, adhesion molecules and tumor cell surface binding ligands; (ii) administering to the afflicted mammal an effective amount of an enzyme acceptor dimer thereby forming active enzymatic sites at a tumor cell surface; and (iii) administering to the afflicted mammal a therapeutically effective amount of an enzyme-activateable, cytotoxic pro-drug thereby releasing the cytotoxic drug at the tumor site.

  本发明描述了式(I)、(II)和(III)的环丙基吲哚细胞毒前药，如说明书所示。本发明还涉及一种针对哺乳动物的肿瘤疾病的位点特异性治疗方法，该方法包括以下步骤：(i)向患病的哺乳动物施用有效量的靶向剂-酶给体肽共轭物，其中靶向剂选自抗体、单克隆抗体、粘附分子和肿瘤细胞表面结合配体的组；(ii)向患病的哺乳动物施用有效量的酶受体二聚体，从而在肿瘤细胞表面形成活性酶位点；(iii)向患病的哺乳动物施用治疗有效量的酶活化、细胞毒前药，从而在肿瘤部位释放细胞毒药物。
• CBI analogs of CC-1065 and the duocarmycins
  申请人：The Scripps Research Institute

  公开号：US20040002528A1

  公开（公告）日：2004-01-01

  Analogs of the antitumor antibiotics CC-1065 and the duocarmycins incorporate the 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) alkylation subunit. The CBI-based analogs have potent cytotoxic activity and are useful as efficacious antitumor compounds. A direct relationship between functional stability and in vitro cytotoxic potency is disclosed. The CBI-based analogs are easily synthesized and are 4× more stable and 4× more potent than the corresponding analogs containing the authentic CPI alkylation subunit of CC-1065 and comparable in potency to agents containing the authentic alkylation subunit of duocarmycin SA. Similarly, the CBI-based agents alkylate DNA with an unaltered sequence selectivity at an enhanced rate and with a greater efficiency than the corresponding CPI analog and were comparable to the corresponding analog incorporating the duocarmycin SA alkylation subunit. Systematic and extensive modifications and simplifications in the DNA binding subunits attached to CBI are also described.

  抗肿瘤抗生素CC-1065和Duocarmycins的类似物包含1,2,9,9a-四氢环丙[c]苯[e]吲哚-4-酮（CBI）烷基化亚单位。基于CBI的类似物具有强效的细胞毒性活性，可用作有效的抗肿瘤化合物。揭示了功能稳定性和体外细胞毒性效力之间的直接关系。基于CBI的类似物易于合成，比含有CC-1065的真实CPI烷基化亚单位的相应类似物稳定性和效力高4倍，并与含有Duocarmycin SA真实烷基化亚单位的药物效力相当。同样，基于CBI的药物以不改变序列选择性的增强速率和更高效率烷基化DNA，并与相应的CPI类似物相当，并与包含Duocarmycin SA烷基化亚单位的相应类似物相当。还描述了附加到CBI的DNA结合亚单位的系统性和广泛性修改和简化。